Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials

被引:17
|
作者
Luan, Shuxin [1 ]
Wan, Hongquan [1 ]
Wang, Shijun [1 ]
Li, He [2 ]
Zhang, Baogang [3 ]
机构
[1] Jilin Univ, Hosp 1, Dept Mental Hlth, Changchun, Peoples R China
[2] Jilin Univ, Hosp 1, Dept Pain Med, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Endoscopy, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China
关键词
treatment-resistant depression; olanzapine; fluoxetine; meta-analysis; STAR-ASTERISK-D; ACUTE MANIA; FLUOXETINE; OLANZAPINE; DISORDER; THERAPY; LONG; NORTRIPTYLINE; DEFINITION; OUTCOMES;
D O I
10.2147/NDT.S127453
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Whether olanzapine/fluoxetine combination (OFC) is superior to olanzapine or fluoxetine monotherapy in patients with treatment-resistant depression (TRD) remains controversial. Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of OFC with olanzapine or fluoxetine monotherapy for patients with TRD. Materials and methods: RCTs published in PubMed, Embase, Web of Science, and the ClinicalTrials.gov registry were systematically reviewed to assess the efficacy and safety of OFC. Outcomes included mean changes from baseline in Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), Brief Psychiatric Rating Scale (BPRS) scores, response rate, remission rate, and adverse events. Results were expressed with weighted mean difference (WMD) with 95% confidence intervals (CIs) and risk ratio (RR) with 95% CIs. Results: A total of five RCTs with 3,020 patients met the inclusion criteria and were included in this meta-analysis. Compared with olanzapine or fluoxetine monotherapy, OFC was associated with greater changes from baseline in MADRS (WMD=-3.37, 95% CI: -4.76, -1.99; P < 0.001), HAM-A (WMD=-1.82, 95% CI: -2.25, - 1.40; P < 0.001), CGI-S (WMD=-0.37, 95%CI:-0.45,-0.28;P < 0.001), and BPRS scores (WMD=-1.46, 95% CI: -2.16, -0.76; P < 0.001). Moreover, OFC had significantly higher response rate (RR= 1.35, 95% CI: 1.12, 1.63; P=0.001) and remission rate (RR=1.71, 95% CI: 1.31, 2.23; P < 0.001). The incidence of treatment-related adverse events was similar between the OFC and monotherapy groups (RR= 1.01, 95% CI: 0.94, 1.08; P= 0.834). Conclusion: OFC is more effective than olanzapine or fluoxetine monotherapy in the treatment of patients with TRD. Our results provided supporting evidence for the use of OFC in TRD. However, considering the limitations in this study, more large-scale, well-designed RCTs are needed to confirm these findings.
引用
收藏
页码:609 / 620
页数:12
相关论文
共 50 条
  • [1] An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression
    Trivedi, Madhukar H.
    Thase, Michael E.
    Osuntokun, Olawale
    Henley, David B.
    Case, Michael
    Watson, Susan B.
    Campbell, Giedra M.
    Corya, Sara A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (03) : 387 - 396
  • [2] Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data
    Bobo, William Victor
    Shelton, Richard C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (13) : 2145 - 2159
  • [3] Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
    Bobo, William V.
    Shelton, Richard C.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2009, 5 : 369 - 383
  • [4] Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
    Luan, Shuxin
    Wan, Hongquan
    Zhang, Lei
    Zhao, Hua
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 467 - 477
  • [5] Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
    Brunner, Elizabeth
    Tohen, Mauricio
    Osuntokun, Olawale
    Landry, John
    Thase, Michael E.
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 (11) : 2549 - 2559
  • [6] Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies
    Ouyang, Yannan
    Li, Juan
    MEDICINE, 2025, 104 (09) : e41495
  • [7] Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety
    Goh, Kah Kheng
    Chen, Chun-Hsin
    Chiu, Yi-Hang
    Lu, Mong-Liang
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (06) : 700 - 713
  • [8] FLUOXETINE EFFICACY IN TREATMENT-RESISTANT DEPRESSION
    AMSTERDAM, JD
    MAISLIN, G
    POTTER, L
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (02) : 243 - 261
  • [9] Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination An Analysis of 2 Adult Studies in Treatment-Resistant Depression
    Degenhardt, Elisabeth K.
    Jamal, Hassan H.
    Tormey, Susan
    Case, Michael
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (03) : 337 - 340
  • [10] Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
    Liu, Peng
    Zhang, Shan-Shan
    Liang, Yun
    Gao, Zi-Jun
    Gao, Wei
    Dong, Bu-Huai
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2855 - 2865